Reversing the Bone Damage caused by Anti-Cancer Drugs
|Key Bone ‘Rescue’ Protocol Ingredients
Click here to order the complete protocol as a bundle with 10% discount.
According to Cancer Research UK… “Any cancer treatment in women that lowers oestrogen levels can increase the risk of osteoporosis.
Treatments that lower oestrogen levels and may increase the risk of osteoporosis include
- Chemotherapy that caused an early menopause
- Hormone therapy with a drug called an LHRH analogue (eg Zoladex)
- Hormone therapy with a drug called an aromatase inhibitor (such as anastrozole, exemestane or letrozole)
- Radiotherapy to your ovaries to stop them working
- Surgery to remove your ovaries when you were premenopausal
Tamoxifen for breast cancer usually only reduces bone density by a small amount. In postmenopausal women, aromatase inhibitors increase bone loss at an average rate of 1 to 3% per year. In young women who have had ovarian suppression followed by aromatase inhibitor therapy, bone density is lost at an average of 7 to 8% per year. Treatment with tamoxifen for 2 to 5 years before having aromatase inhibitors may slow down the rate of bone loss.
Women who have had an early menopause (before the age of 45) due to cancer treatment or who have ovarian suppression therapy and aromatase inhibitors are at higher risk of bone loss.” source
The best that CRUK can offer in terms of advice is to take Calcium and don’t drink coffee, alcohol or smoke, all good advice but it’s not going to restore the bone mineral density you’ve lost, and just when you think it can’t get any worse CRUK suggest Biphosphanates to reduce bone loss, which have an horrendous list of side effects which include bone pain, shaking and loose teeth . Fortunately there’s so much more you can do to reverse the condition of losing bone mineral density after cancer treatment.
You may not have had Chemotherapy, but instead you may have had the Third-generation synthetic aromatase inhibitors. I emphasize the synthetic, because there are many natural AI’s such as Nettle which by some quirk of nature support the bone creation process rather than reduce bone density they accelerate new bone formation.
So.. synthetic AIs; that is, anastrozole, letrozole and exemestane have become the standard of care for the adjuvant treatment of hormone-responsive breast cancer in postmenopausal women. For many years, tamoxifen was the cornerstone of endocrinetherapy .
However, recent clinical trials of synthetic AIs have shown benefits over tamoxifen. The main advantages are improvement of disease-free survival, decreased rates of contralateral breast cancer and a more favorable toxicity profile, with lower rates of thrombo embolic phenomena and endometrial malignancy [2-8].
These trials reported incidences of musculoskeletal symptoms ranging from 5% to 35%. Observational studies, have shown that synthetic aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are more prevalent than originally reported [9,10]. In a cross-sectional survey of 200 women receiving adjuvant synthetic AI therapy for breast cancer, 94 (47%) reported AI-associated joint pain, and 88 (44%) reported joint stiffness; nearly 13% of patients discontinued therapy because of intolerable musculoskeletal symptoms . Because the mechanisms mediating AIMSS are not clearly understood, effective management of AIMSS has not yet been developed.
Potential interventions for AIMSS usually include non-steroidal anti- inflammatory drugs, analgesics , calcitriolagents, vitamin D, and exercise. Some patients even have to switch synthetic AIs or switch to tamoxifen because of severe musculoskeletal symptoms [11,12]. However, it is not clear whether any of these interventions have had a dramatic effect on musculoskeletal symptoms.
Therefore, due to the unsatisfactory response to current symptomatic treatments, many patients seek help from traditional Chinese medicine (TCM). TCM, which has a unique advantage in alleviating symptoms and improving quality of life, and has been widely applied in China for the treatment of cancer-related side effects, such as nausea, vomiting, fatigue, tidal fever, and pain [13,14]. Postmenopausal women with AIMSS exhibit a specific pathological change associated with deficiency of kidney essence and depression of liver qi, according to TCM theory .
Insufficient kidney essence results in failure to nourish the related body constituents and organs, including bone and joints.
Liver qi depression leads to stagnation of qi movement, manifested as pain .
Through the use of the BoneMaker protocol,which, according to therapeutic principle of TCM, would tonify the kidney, fortify the bone, soothe and raise the liver qi, relieve some of the pain and supply nutrients required to build the bones.
Nutraceutical DisclaimerThese statements have not been evaluated by the Food and Drug Administration and the items are not intended to diagnose, treat, cure, or prevent any disease nor are they associated, endorsed, affiliated or sponsored by Anthony William or Medical Medium®.
- Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi: 10.3322/caac.20073. [PubMed] [Cross Ref]
- Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784–3796. doi: 10.1200/JCO.2009.26.3756. [PubMed] [Cross Ref]
- Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis – some new perspectives. Endocrinology. 2001;142:4589–4594. doi: 10.1210/en.142.11.4589. [PubMed] [Cross Ref]
- Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(3 Suppl):S116–124. doi: 10.1067/mjd.2001.117432. [PubMed] [Cross Ref]
- Miller WR, Hawkins RA, Forrest AP. Significance of aromatase activity in human breast cancer. Cancer Res. 1982;42(8 Suppl):3365s–3368s. [PubMed]
- Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol. 2005;95:17–23. doi: 10.1016/j.jsbmb.2005.04.002. [PubMed] [Cross Ref]
- Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998;4:2089–2093. [PubMed]
- Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M, Einstein Lonning P. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001;7:1230–1236. [PubMed]
- Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751–757. doi: 10.1200/JCO.20.3.751. [PubMed] [Cross Ref]
- Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003;86:255–263. doi: 10.1016/S0960-0760(03)00365-0. [PubMed] [Cross Ref]
- Alone or in Combination Trialists’ Group. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633–643. doi: 10.1016/S1470-2045(06)70767-7. [PubMed] [Cross Ref]
- Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62. doi: 10.1016/S0140-6736(05)74803-0. [PubMed] [Cross Ref]
- Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492. doi: 10.1200/JCO.2006.08.8617. [PubMed] [Cross Ref]
- Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570. doi: 10.1016/S0140-6736(07)60200-1. [PubMed] [Cross Ref]
- Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271. doi: 10.1093/jnci/dji250. [PubMed] [Cross Ref]
- Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462. doi: 10.1016/S0140-6736(05)67059-6. [PubMed] [Cross Ref]
- Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rucklinger E, Samonigg H. Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845–1853. doi: 10.1093/jnci/djm246. [PubMed] [Cross Ref]
- Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26:1965–1971. doi: 10.1200/JCO.2007.14.0228. [PubMed] [Cross Ref]
- Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–5147. doi: 10.1200/JCO.2005.04.120. [PubMed] [Cross Ref]
- Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(Suppl 7):vii10–4. doi: 10.1093/annonc/mdl941. [PubMed] [Cross Ref]
- Alone or in Combination (ATAC) Trialists’ Group. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi: 10.1016/S1470-2045(07)70385-6. [PubMed] [Cross Ref]
- Locker GY, Eastell R. The time course of bone fractures observed in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial [abstract] Proc Am Soc Clin Oncol. 2003;22:abstract 98.
- Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092. doi: 10.1056/NEJMoa040331. [PubMed] [Cross Ref]
- Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154:2585–2588. doi: 10.1001/archinte.154.22.2585. [PubMed] [Cross Ref]
- Assikis VJ, Jordan VC. Risks and benefits of tamoxifen therapy. Oncology. 1997;11(2 Suppl 1):21–23. [PubMed]
- Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. ATAC Trialists’ group. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) J Bone Miner Res. 2006;21:1215–1223. doi: 10.1359/jbmr.060508. [PubMed] [Cross Ref]
- Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051–1057. doi: 10.1200/JCO.2007.11.0726. [PubMed] [Cross Ref]
- Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–3635. doi: 10.1200/JCO.2005.05.4882. [PubMed] [Cross Ref]
- Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone. 2007;41:308–317. doi: 10.1016/j.bone.2007.06.010. [PubMed] [Cross Ref]
- Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279–302. doi: 10.1210/er.23.3.279. [PubMed] [Cross Ref]
- Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367–4370. doi: 10.1210/en.140.9.4367. [PubMed] [Cross Ref]
- Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y. Regulation of adult bone turnover by sex steroids. J Cell Physiol. 2010;224:305–310. doi: 10.1002/jcp.22159. [PubMed] [Cross Ref]
- Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S. Effects of suppression of follicle stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5063–5068. doi: 10.1210/jc.2010-1103. [PMC free article] [PubMed] [Cross Ref]
- Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–5137. doi: 10.1200/JCO.2005.07.097. [PubMed] [Cross Ref]
- McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2010;119:643–651. doi: 10.1007/s10549-009-0646-0. [PubMed] [Cross Ref]
- Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Lang I, Smith I, Gelber RD, Goldhirsch A, Coates AS. BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009;20:1489–1498. doi: 10.1093/annonc/mdp033. [PMC free article] [PubMed] [Cross Ref]
- Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19:1407–1416. doi: 10.1093/annonc/mdn164. [PubMed] [Cross Ref]
- Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34(Suppl 1):S3–18. doi: 10.1016/j.ctrv.2008.03.007. [PubMed] [Cross Ref]
- Nieves JW, Barrett-Connor E, Siris ES, Zion M, Barlas S, Chen YT. Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int. 2008;19:673–679. doi: 10.1007/s00198-007-0501-2. [PubMed] [Cross Ref]
- Schwartz AL, Winters-Stone K, Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum. 2007;34:627–633. doi: 10.1188/07.ONF.627-633. [PubMed] [Cross Ref]
- Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–4057. doi: 10.1200/JCO.2003.08.017. [PubMed] [Cross Ref]
- Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R. Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820–828. doi: 10.1200/JCO.2005.02.7102. [PubMed] [Cross Ref]
- Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008;112:1001–1010. doi: 10.1002/cncr.23259. [PubMed] [Cross Ref]
- Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–836. doi: 10.1200/JCO.2005.05.3744. [PubMed] [Cross Ref]
- Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14:6336–6342. doi: 10.1158/1078-0432.CCR-07-5101. [PubMed] [Cross Ref]
- Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28:967–975. doi: 10.1200/JCO.2009.24.5902. [PubMed] [Cross Ref]
- Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res. 2010;12:R24. doi: 10.1186/bcr2565. [PMC free article] [PubMed] [Cross Ref]
- Amir E, Ocana A, Seruga B, Josse R, Clemons M. Medical oncology: zoledronic acid for breast cancer therapy-induced bone loss. Nat Rev Clin Oncol. 2010;7:187–188. doi: 10.1038/nrclinonc.2010.19. [PubMed] [Cross Ref]
- Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynecol Oncol. 2010;117:139–145. doi: 10.1016/j.ygyno.2009.12.001. [PubMed] [Cross Ref]
- Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–4882. doi: 10.1200/JCO.2008.16.3832. [PubMed] [Cross Ref]
- Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer. 2010;46:2187–2195. doi: 10.1016/j.ejca.2010.04.012. [PubMed] [Cross Ref]